GMDA Archives - Page 6 of 8

5 minute read

Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday

November 23, 6:25 AM

Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on Iberian Airlines' in-flight magazine, Ronda.

4 minute read

Why Dollar Tree Shares Are Trading Lower By 10%? Here Are 53 Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

November 22, 2:16 PM

Gainers Palisade Bio, Inc. (NASDAQ: PALI) shares jumped 99.1% to $4.42 after the company announced the FDA granted Fast Track designation to LB1148 for the acceleration of time to return of bowel function following surgery.

1 minute read

Needham Maintains Buy on Gamida Cell, Lowers Price Target to $8

By Benzinga Newsdesk

November 22, 12:21 PM

Needham analyst Gil Blum maintains Gamida Cell (NASDAQ:GMDA) with a Buy and lowers the price target from $9 to $8.

GMDA

10 minute read

News
Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

November 22, 11:48 AM

During Tuesday's trading, 160 companies set new 52-week lows.

ABSI

2 minute read

Gamida Cell Provides Regulatory Update On Omidubicel, Says Received Extension Of Omidubicel PDUFA Date From Jan. 30, 2023 To May 1, 2023 As FDA Issued Information Request

By Michael Horton

November 21, 5:54 PM

Gamida Cell Ltd. (NASDAQ:GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematological and solid cancers and other serious diseases, today provided an update on recent

GMDA

1 minute read

Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%

By Lisa Levin

November 15, 7:53 AM

Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday.

CMBM

17 minute read

Earnings

Earnings Scheduled For November 14, 2022

By Benzinga Insights

November 14, 6:06 AM

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.

AAIC

1 minute read

Needham Maintains Buy on Gamida Cell, Lowers Price Target to $9

By Benzinga Newsdesk

September 29, 12:27 PM

Needham analyst Gil Blum maintains Gamida Cell (NASDAQ:GMDA) with a Buy and lowers the price target from $12 to $9.

GMDA

5 minute read

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday

By Lisa Levin

September 29, 5:09 AM

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.

ABOS

4 minute read

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

September 28, 12:40 PM

Gainers

ABOS

Feed Symbols: GMDA